Keeping An Early-Stage Cell Therapy Biotech In The Black With IN8bio's William Ho
About this episode
William Ho, CEO of IN8bio, discusses the advantages of gamma delta T cells in cancer treatment and the challenges of financing early-stage biotech companies.
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, William Ho, CEO of IN8bio, explains why gamma delta T cells may have an edge against cancer, including solid tumors like glioblastoma. He also offers up a candid and step-by-step look at what it takes to finance an early clinical-stage cell therapy company through a punishing IPO market and a long cash crunch. Access this and hundreds of episodes of the Business of Biotech videocas...
More episodes of Business Of Biotech
- Late-Stage Development And Commercial Planning With CervoMed's Matt Winton, Ph.D.
- BoB@BIO: Biotech In The Balance With Ovid Therapeutics' Dr. Jeremy Levin
- BoB@BIO: Biotech Investing And Deals With Sofinnova's Maha Radhakrishnan, M.D.
- Targeting Tau in Alzheimer's Disease With Voyager Therapeutics' Al Sandrock, M.D., Ph.D.
- Drug Launch Success In A Changing Commercial Landscape With ACMA's William Soliman, Ph.D.
Explore listener stats, chart rankings, contacts and more on the Business Of Biotech podcast page.